Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹372 Cr
P/E Ratio
74.54
P/B Ratio
3.92
Industry P/E
37.33
Debt to Equity
0
ROE
9.6 %
ROCE
12.89 %
Div. Yield
0 %
Book Value
15.54
EPS
0.64
CFO
₹26.10 Cr
EBITDA
₹20.89 Cr
Net Profit
₹-32.78 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Zenotech Lab
| -15.31 | 7.49 | -2.49 | -7.98 | -4.09 | 24.38 | -0.06 |
|
BSE Healthcare
| -5.48 | 1.35 | 0.22 | 22.74 | 20.05 | 23.06 | 9.77 |
|
BSE Small Cap
| -10.07 | 4.18 | -3.21 | 7.10 | 18.99 | 35.87 | 15.84 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Zenotech Lab
| 7.29 | 2.75 | 6.14 | 66.12 | 48.83 | -30.29 | -19.55 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 436.20 | 7,095.26 | 25.86 | 12.5 | |
| 5,240.00 | 8,712.93 | 36.83 | 43.77 | |
| 681.25 | 6,656.14 | 75.39 | 4.01 | |
| 665.80 | 6,139.88 | 22.78 | 12.68 |
No Review & Analysis are available.
Zenotech Laboratories Limited operates as a pharmaceutical specialty generic injectables company in India. The company manufactures oncology, biotechnology, and general injectable products, such as granulocyte-colony stimulating factor (GCSF) and... granulocyte-macrophage colony-stimulating factor (GMCSF). Its injectable product portfolio primarily serves therapy areas, such as oncology and anesthesiology. The company was formerly known as Sunline Technologies Limited and changed its name to Zenotech Laboratories Limited in August 2004. Zenotech Laboratories Limited was incorporated in 1989 and is based in Hyderabad, India. Read more
Incorporated
1989
Chairman
Azadar Hussain Khan
Managing Director
--
Group
Sun Pharma
Headquarters
Hyderabad, Telangana
Website
Looking for more details about Zenotech Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Zenotech Laboratories Ltd stood at ₹ 108 Cr as on 31-Dec-24
The share price of Zenotech Laboratories Ltd is ₹60.97 (BSE) as of 23-Apr-2025 IST. Zenotech Laboratories Ltd has given a return of -4.09% in the last 3 years.
Zenotech Laboratories Ltd has a market capitalisation of ₹ 372 Cr as on 23-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Zenotech Laboratories Ltd is 3.92 times as on 23-Apr-2025, a 27% discount to its peers’ median range of 5.35 times.
The P/E ratio of Zenotech Laboratories Ltd is 74.54 times as on 23-Apr-2025, a 100% premium to its peers’ median range of 37.33 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Zenotech Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Zenotech Laboratories Ltd.
Zenotech Laboratories Limited operates as a pharmaceutical specialty generic injectables company in India. The company manufactures oncology, biotechnology, and general injectable products, such as granulocyte-colony stimulating factor (GCSF) and granulocyte-macrophage colony-stimulating factor (GMCSF). Its injectable product portfolio primarily serves therapy areas, such as oncology and anesthesiology. The company was formerly known as Sunline Technologies Limited and changed its name to Zenotech Laboratories Limited in August 2004. Zenotech Laboratories Limited was incorporated in 1989 and is based in Hyderabad, India.
The promoter of Zenotech Laboratories Ltd is SUN PHARMACEUTICAL INDUSTRIES LIMITED. SUN PHARMACEUTICAL INDUSTRIES LIMITED owns 68.84 per cent of the total equity. The chairman of the company is Azadar Hussain Khan ..
There is no promoter pledging in Zenotech Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,680
|
|
|
7,005
|
|
|
6,570
|
|
|
6,016
|
| Zenotech Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
4.22
|
|
Operating margin(%)
|
13.81
|
|
Net Margin(%)
|
12.06
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Zenotech Laboratories Ltd was ₹5 Cr.
₹0.57
(
